FDA warning letter · Drugs

Sichuan Deebio Pharmaceutical Co. Ltd.

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Failure to follow and document laboratory controls at the time of performance, and failure to document and explain any departures from laboratory procedures.

Passage 2

Failure of your quality unit to exercise its responsibility to ensure the API and intermediates manufactured at your facility are in compliance with CGMP.